Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

BACKGROUND: The phase IIIb CompLEEment-1 study evaluated ribociclib plus letrozole in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). Outcomes were investigated in the following subgroups: central nervous system (...

Descripción completa

Detalles Bibliográficos
Autores principales: Cottu, Paul, Ring, Alistair, Abdel-Razeq, Hikmat, Marchetti, Paolo, Cardoso, Fatima, Salvador Bofill, Javier, Martín, Miguel, Menon-Singh, Lakshmi, Wu, Jiwen, De Laurentiis, Michelino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073296/
https://www.ncbi.nlm.nih.gov/pubmed/35131646
http://dx.doi.org/10.1016/j.breast.2022.01.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073296/
https://www.ncbi.nlm.nih.gov/pubmed/35131646
http://dx.doi.org/10.1016/j.breast.2022.01.016

Ejemplares similares